Related Experiment Video
Updated: Jun 5, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting
Mami Murakami1, Horacio Cabral, Yu Matsumoto
1Department of Bioengineering, Graduate School of Engineering, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Abstract:
Nanocarrier-mediated drug targeting is an emerging strategy for cancer therapy and is being used, for example, with chemotherapeutic agents for ovarian cancer. Nanocarriers are selectively accumulated in tumors as a result of their enhanced permeability and retention of macromolecules, thereby enhancing the antitumor activity of the nanocarrier-associated drugs. We investigated the real-time subcellular fate of polymeric micelles incorporating (1,2-diaminocyclohexane) platinum(II) (DACHPt/m), the parent complex of oxaliplatin, in tumor tissues by fluorescence-based assessment of their kinetic stability. These observations revealed that DACHPt/m was extravasated from blood vessels to the tumor tissue and dissociated inside each cell. Furthermore, DACHPt/m selectively dissociated within late endosomes, enhancing drug delivery to the nearby nucleus relative to free oxaliplatin, likely by circumvention of the cytoplasmic detoxification systems such as metallothionein and methionine synthase. Thus, these drug-loaded micelles exhibited higher antitumor activity than did oxaliplatin alone, even against oxaliplatin-resistant tumors. These findings suggest that nanocarriers targeting subcellular compartments may have considerable benefits in clinical applications.
Insights
Polymeric micelles loaded with a platinum drug accumulate in tumors and release their payload in late endosomes. This targeted delivery enhances antitumor activity, even in drug-resistant cancers.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery
Background:
- Nanocarrier-mediated drug targeting enhances chemotherapy efficacy by accumulating drugs in tumors.
- Polymeric micelles are a promising nanocarrier system for cancer therapy.
Purpose of the Study:
- To investigate the subcellular fate of polymeric micelles incorporating (1,2-diaminocyclohexane) platinum(II) (DACHPt/m).
- To assess the kinetic stability and tumor accumulation of DACHPt/m.
- To evaluate the antitumor activity of DACHPt/m compared to free oxaliplatin.
Main Methods:
- Real-time fluorescence-based assessment of DACHPt/m in tumor tissues.
- Kinetic stability analysis of nanocarriers.
- Comparison of antitumor activity in vitro and in vivo.
Main Results:
- DACHPt/m extravasated from blood vessels and dissociated within tumor cells.
- Selective dissociation of DACHPt/m occurred in late endosomes, facilitating nuclear drug delivery.
- DACHPt/m demonstrated enhanced antitumor activity compared to oxaliplatin, including against resistant tumors.
Conclusions:
- Nanocarriers can be engineered to target specific subcellular compartments for improved drug delivery.
- DACHPt/m exhibits superior efficacy by circumventing cellular drug resistance mechanisms.
- Subcellular targeting nanocarriers hold significant potential for clinical cancer therapy.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Bioavailability Enhancement: Drug Permeability Enhancement
Bioavailability Enhancement: Drug Solubility Enhancement
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

